Regarding the NRAS gene, some rare variations in codons 12, 13, 61, 117, and 146 (exons 2–4) have been related to intrinsic tumor resistance and worse ORR, PFS, and OS, recommending pre-treatment, and possibly post-treatment, genotyping [10,28]. The gene discussed is NRAS; the disease is neoplasm.